Berman Capital Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Berman Capital Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$10K	Buy	113 +28	+33%	+$2.53K	﹤0.01%	1192
2021 Q2	$8K	Hold	85	–	–	﹤0.01%	1208
2021 Q1	$9K	Hold	85	–	–	﹤0.01%	1072
2020 Q4	$11K	Hold	85	–	–	﹤0.01%	897
2020 Q3	$6K	Buy	85 +9	+12%	+$746	﹤0.01%	984
2020 Q2	$5K	Hold	76	–	–	﹤0.01%	990
2020 Q1	$3K	Buy	+76	New	+$3.95K	﹤0.01%	1058
2019 Q4	–	Sell	-31	Closed	-$1K	–	1530
2019 Q3	$1K	Hold	31	–	–	﹤0.01%	1359
2019 Q2	$1K	Hold	31	–	–	﹤0.01%	1374
2019 Q1	$2K	Buy	+31	New	+$1.77K	﹤0.01%	1113

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Berman Capital Advisors's RARE Position: Q3 2021 in Review

Berman Capital Advisors increased its Ultragenyx Pharmaceutical (RARE) stake by 33% in Q3 2021, buying an estimated $2.53K and bringing the position to 113 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

Berman Capital Advisors first reported a position in RARE in Q1 2019 and has held it in 10 quarters since. The position peaked at $11K in Q4 2020. 222 funds tracked by Wall St. Rank hold RARE as of Q3 2021.

Berman Capital Advisors held 113 shares of Ultragenyx Pharmaceutical worth $10K as of Q3 2021.
Berman Capital Advisors bought 28 Ultragenyx Pharmaceutical shares in Q3 2021, an estimated $2.53K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1192 holding.
Berman Capital Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and has held it in 10 quarters since.
Berman Capital Advisors's Ultragenyx Pharmaceutical position peaked at $11K in Q4 2020.
222 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.